肺癌、肺部結節、高壓氧治療、經皮氣切手術、睡眠呼吸障礙、肺阻塞、氣喘、一般胸腔疾病(咳嗽、肺結核、肺炎)、一般內科疾病、呼吸道相關疾病

臺中榮總胸腔內科主治醫師
肺癌整合照護暨研究中心主治醫師
高壓氧治療中心主治醫師

臺中榮總胸腔內科主治醫師
臺中榮總胸腔內科總醫師
臺中榮總內科部住院醫師

國立成功大學醫學系
國立中興大學轉譯醫學博士學位學程進修中

內科專科
胸腔暨重症專科
高壓氧專科
重症專科

國立陽明交通大學講師

肺癌、高壓氧。

利用家族史以及基因檢測增加低劑量電腦斷層篩檢肺癌之準確度
雄性賀爾蒙與其抑制劑在肺癌之角色

(1)Lee, Po-Hsin, et al. Comparing the Real-World Efficacy of Erlotinib and Afatinib in Treating Advanced Lung Squamous Cell Carcinoma. Thorac Med 2023; 38: 187-198
(2)Lee, Po-Hsin, et al. "Adjuvant chemotherapy compared with observation in patients with T2aN0 stage IB lung adenocarcinoma." Frontiers in Oncology 13 (2023).
stage Ib肺腺癌病患術後接受輔助性化學治療之優劣
(3)Lee, Po-Hsin, et al. Reactivation of Hepatitis B Virus in Lung Cancer Patients Receiving Tyrosine Kinase Inhibitor Treatment. J. Clin. Med. 2023, 12, 231. https://doi.org/10.3390/jcm12010231
肺癌病患使用標靶藥物後產生B型肝炎活化之研究
(4)Chu, C. H., Huang, Y. H., Lee, P. H. et al (2022). Various impacts of driver mutations on the PD-L1 expression of NSCLC. Plos one, 17(8), e0273207.
肺癌病患不同基因突變其PD-L1表現與其預後之分析
(5)Lee, Po-Hsin, et al. "Histological Transformation after Acquired Resistance to the Third-Generation EGFR-TKI in Patients with Advanced EGFR-Mutant Lung Adenocarcinoma." Medicina 58.7 (2022): 908.
肺癌病患接受第三代EGFR標靶治療後產生病理型態改變之分析
(6)Wu, J. J., Lee, P. H., et al. (2022). Characteristics and immune checkpoint inhibitor effects on non-smoking non-small cell lung cancer with KRAS mutation: A single center cohort (STROBE-compliant). Medicine, 101(24), e29381-e29381.
KRAS陽性病患使用免疫檢查點抑制劑之探討
(7)Lee, Po-Hsin, et al. "Real-world efficacy and safety of lorlatinib in treating advanced ALK-positive non–small cell lung cancer patients." Anti-Cancer Drugs 32.10 (2021): 1099-1104.
ALK陽性病患使用lorlatinib治療之分析
(8)Lee, Po-Hsin, et al. "Prognostic Factors to Predict ICU Mortality in Patients with Severe ARDS Who Received Early and Prolonged Prone Positioning Therapy." Journal of clinical medicine 10.11 (2021): 2323.
急性呼吸窘迫症候群之病患使用俯臥通氣預後之分析
(9)Lee, Po-Hsin, "Transformations First Into Squamous-Cell Carcinoma and Later Into Sarcomatoid Carcinoma After Acquired Resistance to Osimertinib in a Patient With EGFR-Mutant Lung Adenocarcinoma: Case Report." Clinical lung cancer (2020): S1525-7304.
肺癌病患使用osimertinib之後產生病理型態變化之個案報告
(10)Lee, Po-Hsin, "Hepatitis B flare during osimertinib targeted therapy in a lung cancer patient with a resolved hepatitis B virus infection." European journal of cancer (Oxford, England: 1990) 130 (2020): 272-274.
肺癌病患使用osimertinib標靶藥物後產生B型肝炎再活化之報導
(11)李柏昕, et al. "急性呼吸窘迫症候群 (ARDS) 使用俯臥式通氣模式 (Prone positioning) 之預後影響因子探討." 內科學誌 30.2 (2019): 96-106.
(12)Lee, Po-Hsin, "Pulmonary Embolism and Severe Asthma: Case Report and Literature Review." Medicina 55.10 (2019): 647.
嚴重氣喘病患併發肺栓塞之報導以及文獻回顧
(13)Lee, Po-Hsin, et al. "Snakebite (Protobothrops mucrosquamatus)-related myositis." Journal of the Formosan Medical Association= Taiwan yi zhi 118.7 (2019): 1168.
以超音波診斷蛇咬造成之肌肉發炎個案報導
(14)Lee, Po‐Hsin, "A 27‐year‐old female presented with diffuse alveolar haemorrhage due to breast angiosarcoma with lung metastasis." Respirology Case Reports 7.5 (2019): e0419.
肺部血管肉瘤以肺部出血為表現之個案報導
(15)Lee, Po-Hsin "Coinfection of pneumocystis jiroveci pneumonia and pulmonary apergillosis in a non-HIV-infected patient." Journal of microbiology, immunology, and infection= Wei mian yu gan ran za zhi 51.6 (2018): 860.
肺部同時感染肺囊蟲及肺麴菌之個案報導
(16)Higher CD4/CD8 ratio of pleural effusion predicts better survival for lung cancer patients receiving immune checkpoint inhibitors
使用免疫檢查點抑制劑之肺癌病人治療後產生肋膜積液其CD4/CD8比例高者預後較佳

(2023) 臺中榮總院級臨床教學績優醫師
(2023) 第一屆煦陽溫和大地優良醫學論文獎 青年醫師-住院醫師組 第一名
(2022) 臺中榮總青年醫師優良論文第二名
(2020) EBM實證醫學第二名
(2020) 胸重醫學會Junior Research Award優秀論文獎
(2020) 內科部研究進度報告第二名
(2020) 臺中榮總院級臨床教學績優住院醫師
(2019) 內科學誌優秀論文獎綜論類第一名